DJIA 16,102.38 -272.38 -1.66%
NASDAQ 4,683.92 -49.58 -1.05%
S&P 500 1,921.22 -29.91 -1.53%
market minute promo

Isis Pharmaceuticals (NASDAQ: ISIS)

52.10 0.53 (1.03%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ISIS $52.10 1.03%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $50.87
Previous Close $51.57
Daily Range $50.25 - $52.44
52-Week Range $35.26 - $77.80
Market Cap $6.3B
P/E Ratio 271.42
Dividend (Yield) $0.00 (0.0%)
Volume 1,103,381
Average Daily Volume 1,795,170
Current FY EPS -$0.52

Sector

Healthcare

Industry

Drug Makers

Isis Pharmaceuticals (ISIS) Description

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases. Website: http://www.isispharm.com/

News & Commentary Rss Feed

Isis' News-Filled Week

The biotech announces a new partnership, clinical trial results, and earnings over the course of two days.

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

3 Promising Biotechs Hobbled By First-Impression Issues

Isis Pharmaceuticals Enters Oversold Territory (ISIS)

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals (ISIS) Earnings Report: Q2 2015 Conference Call Transcript

Isis Pharmaceuticals' (ISIS) CEO Stan Crooke on Q2 2015 Results - Earnings Call Transcript

Isis Pharmaceuticals (ISIS) Misses Earnings Estimates in Q2 - Tale of the Tape

Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antis

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

See More ISIS News...

ISIS's Top Competitors

ISIS $52.10 (1.03%)
Current stock: ISIS
AMGN $147.02 (-1.48%)
Current stock: AMGN
GILD $102.06 (0.15%)
Current stock: GILD
BIIB $302.26 (0.21%)
Current stock: BIIB